Compare Howmet Aerospace Inc (HWM) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Howmet Aerospace Inc vs Mesoblast Limited — how do they compare? Howmet Aerospace Inc trades at $225.24 (market cap $88.76B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Howmet Aerospace Inc is far larger — about 50.7× Mesoblast Limited's market cap, and Howmet Aerospace Inc pays a 0.25% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Mesoblast Limited for 15 Days on average.
| HWM | MESO | |
|---|---|---|
Market Cap | $88.76B | $1.75B |
Volume | 2,648,516 | 239,027 |
Sector | Industrials | Health |
52-Week High | $292.65 | $20.96 |
52-Week Low | $184.09 | $13.19 |
Typical Hold Time | 35 Days | 15 Days |
Enterprise Value | $92.86B | $1.83B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $222.53, down 0.08% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, with revenue and earnings growth, a net income margin of 20.52%, and consistent quarterly EPS beats. Analyst consensus is overwhelmingly bullish with a $328.10 price target, supported by positive news on defense and aerospace demand.
The outlook for HWM is positive due to robust financial performance and sector tailwinds, but risks include technical weakness and competitive pressures. Investment opportunity lies in its growth trajectory and shareholder returns, though investors should monitor execution risks and market volatility.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Howmet Aerospace Inc
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
